| Document |
Document Title |
|
WO/2019/178393A9 |
The invention provides various orthogonal nucleotide analogues and methods for using combinations of said various orthogonal nucleotide analogues for sequencing by synthesis.
|
|
WO/2019/200273A1 |
The present invention relates to novel phosphorous (V) (P(V)) reagents, methods for preparing thereof, and methods for preparing organophosphorous (V) compounds by using the novel reagents.
|
|
WO/2019/194385A1 |
The present disclosure relates to a method and apparatus wherein terahertz waves including a first band corresponding to methylation resonance frequency in the terahertz band are applied to methylated molecules and the methylated molecul...
|
|
WO/2019/193543A1 |
The present invention relates to 3'3'-cyclic dinucleotides modified with a 3'-phosphonoalkyl bond and derivatives thereof, that can modulate the activity of the STING adaptor protein (I) or a pharmaceutically acceptable salt thereof wher...
|
|
WO/2019/195494A1 |
The invention provides compositions and methods for synthesis of phosphorylated organic compounds, including nucleoside triphosphates.
|
|
WO/2019/193542A1 |
The present disclosure relates to 2'3'-cyclic dinucleotides modified with a 2'- or 3'-phosphonoalkyl bond and derivatives thereof, that can modulate the activity of the STING adaptor protein (IA) or a compound of Formula (1B) or pharmace...
|
|
WO/2019/193533A1 |
The present invention relates to 2'2'-cyclic dinucleotides modified with a 2'-phosphonoalkyl bond and derivatives thereof, that can modulate the activity of the STING adaptor protein (I) or pharmaceutically acceptable thereof, wherein L1...
|
|
WO/2019/191642A1 |
Provided herein are methods and labeling kits for synthesizing 2'-deoxy-2'-[18F]fluoro-5-methyl-1-beta-D-arabinofuranosyl-u
racil in a one-pot reaction in compliance with CGMP. Also disclosed are labeling kits that can be assembled in an...
|
|
WO/2019/191389A1 |
The invention relates to a crystalline methanol or dimethyl sulfoxide solvated form of regadenoson and an anhydrous polymorph of regadenoson. The invention is also directed to the preparation of the methanol or dimethyl sulfoxide solvate...
|
|
WO/2019/185477A1 |
Compounds of formula I, wherein Base, R1 and R2 are defined as in claim 1, are modulators of STING.
|
|
WO/2019/175126A1 |
The invention comprises LNA-dicarboxylic acid derivatives of the formula I or salts thereof, wherein R1 is a nucleobase or a modified nucleobase R2 is a hydroxy protecting group and n is an integer from 1 to 5. The LNA-dicarboxylic acid ...
|
|
WO/2019/175776A1 |
Compounds of the general formula (I), or a pharmaceutically acceptable salt thereof, processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.
|
|
WO/2019/174657A1 |
Substituted pyridopyrrolopyrimidine ribonucleosides of general formula I, wherein R is as described in the independent claim, preferably R is selected from the group comprising thiophen-3-yl, furan-2-yl, furan-3-yl, benzofuran-2-yl, meth...
|
|
WO/2019/169837A1 |
The invention relates to an albumin conjunction-type maleimide functionalized gemcitabine prodrug as well as application thereof in transferring an antitumor prodrug. The albumin conjunction-type maleimide functionalized gemcitabine prod...
|
|
WO/2019/172394A1 |
A β-modified phosphoric acid compound precursor having the partial structure represented by formula 1A in the molecule thereof. A medicine and a reaction inhibitor containing the β-modified phosphoric acid compound precursor. (In the f...
|
|
WO/2019/173682A1 |
Methods of identifying compounds that modulate the conversion of AMP to adenosine by 5'-nucleotidase, ecto, and that possess particular pharmacokinetic characteristics are described herein. Methods of such compounds, and compositions com...
|
|
WO/2019/171285A1 |
The invention relates to compounds of Formula (I), vvherein R1 is selected from the group consisting of: Formula (Ia) and (Ib) as well as methods of treating or preventing HIV in subjects.
|
|
WO/2019/166457A1 |
The disclosure relates to tagged nucleoside compounds comprising a nucleotide polyphosphate covalently attached to a tag, wherein the compound is a polymerase substrate and the polymer moiety is capable of entering a nanopore linked to t...
|
|
WO/2019/160059A1 |
Provided is a method for recycling s-adenosylmethionine that is characterized in that after s-adenosylmethionine is demethylated, s-adenosylmethionine is regenerated by converting s-adenosylmethionine from methionine obtained by transfer...
|
|
WO/2019/160994A1 |
Methods are provided for the epigenetic analysis of cell-free DNA using organic boranes to convert oxidized 5-methylcytosine residues in the cell-free DNA to dihydrouracil (DHU) residues. Cell-free DNA is contacted with an organic borane...
|
|
WO/2019/160937A1 |
A labeled nucleotide includes a nucleotide, a linking molecule attached to a phosphate group of the nucleotide, and a redox-active charge tag attached to the linking molecule. The redox-active charge tag is to be oxidized or reduced by a...
|
|
WO/2019/155639A1 |
The present invention relates to a production method and a production intermediate for guanosine-3',5'-bisdiphosphate.
|
|
WO/2019/156240A1 |
The present invention relates to a production method and a production intermediate for guanosine-3',5'-bisdiphosphate.
|
|
WO/2019/154388A1 |
The present application relates to a salt of a pyranose-substituted heterocyclic compound, a preparation method therefor, and use thereof, and in particular, to an acid addition salt of a compound of formula (I) or a prodrug thereof, and...
|
|
WO/2019/152911A1 |
Disclosed are compounds having formula (I) or a pharmaceutically acceptable salt, ester, amide, solvate, or stereoisomer thereof, wherein L, Y1, Y2, Y3, Y4, Y5, Z1, Z2, Z3, Z4, Z5, Z6, and Effector are each as defined in the specificatio...
|
|
WO/2019/152416A1 |
Provided herein are compounds of Formula (I) and their salts, and compositions comprising such compounds that are useful for increasing the amount of NAD+ in cells. Also disclosed are methods of using the disclosed compounds and composit...
|
|
WO/2019/147050A1 |
The present invention relates to: novel nucleoside or nucleotide derivatives, racemates thereof, stereoisomers thereof, or pharmaceutically acceptable salts thereof; and a pharmaceutical composition for preventing or treating viral infec...
|
|
WO/2019/143860A1 |
Provided herein are 5-fluorouracil derived acetal and hemiaminal ether compounds, their preparation and their uses, such as treating liver diseases or various types of cancer.
|
|
WO/2019/142135A1 |
The present invention relates to a process for preparing tc-DNA nucleoside precursors, the resulting tc-DNA nucleosides, and oligonucleotides comprising such tc-DNA nucleosides. In an embodiment of the invention, the process includes use...
|
|
WO/2019/139920A1 |
Provided herein are phosphor(n)amidatacetal and phosph(on)atacetal compounds, their preparation and their uses, such as treating liver diseases or nonliver diseases via intervening in the molecular pathways in the liver.
|
|
WO/2019/137971A1 |
The present invention relates to a compound of the general formula (I) wherein the pyranose ring is a-D-galactopyranose, R1 is selected from the group consisting of (II) wherein the asterix 1 * indicates the carbon atom of the heteroarom...
|
|
WO/2019/140365A1 |
The present invention provides prodrugs and methods of use thereof.
|
|
WO/2019/136389A1 |
The invention relates to nucleotide prodrugs and pharmaceutical preparations thereof. The invention further relates using the prodrugs of the invention in the treatment of mitochondrial DNA (mtDNA) depletion syndrome (MDS).
|
|
WO/2019/135405A1 |
A method for detecting an analog that is derived from trifluridine, the method including a step for subjecting a sample that includes trifluridine or a salt thereof to high-speed liquid chromatography that uses a mobile phase that compri...
|
|
WO/2019/131719A1 |
The purpose of the present invention is to provide: a method for purifying and producing a highly fat-soluble phosphoramidite; a capping reaction using said highly fat-soluble phosphoramidite compound; and a method for producing oligonuc...
|
|
WO/2019/133815A1 |
Described herein are methods of increasing meat quantity and/or improving meat quality of domesticated meat animals using treatments of nicotinamide riboside. The nicotinamide riboside may be in the form of a chloride salt mixed or disso...
|
|
WO/2019/133712A1 |
The present invention is directed to compounds, compositions and methods for treating or preventing HIV and other viral infections, particularly where the virus is present in macrophages, microglia, and primary myeloid cells, and elimina...
|
|
WO/2019/130236A1 |
The present invention relates to nucleolipid-based compounds for use in regenerative medicine. More specifically, the invention relates to the use of to nucleolipid-based compounds in bioink gel formulations and a bioprinting method comp...
|
|
WO/2019/129059A1 |
The present invention relates to a phosphonic acid derivative having a CD73 inhibitory activity and a structure of formula (I), and a preparation method and use thereof. The series of compounds of the present invention can be widely used...
|
|
WO/2019/129260A1 |
The present invention relates to a method for preparing a crystal form of azacitidine. The present invention relates to a method for preparing a crystal form I of azacitidine. DMSO is used as a solvent, and a mixed alcohol solvent is use...
|
|
WO/2019/133878A1 |
Compounds, compositions, and methods for treatment and/or prevention of at least one disease, disorder, and/or condition by inhibiting binding of an E-selectin, galectin-3, or E-selectin and galectin-3 to ligands are disclosed. For examp...
|
|
WO/2019/133634A1 |
The present disclosure relates to chemical compounds that modulate pantothenate kinase (PanK) activity for the treatment of metabolic disorders (such as diabetes mellitus type II), neurologic disorders (such as pantothenate kinase-associ...
|
|
WO/2019/120299A1 |
Provided are a liver specific delivery (LSD)-based anticancer prodrug nucleoside cyclic phosphate compound and an application thereof, and in particular, a compound represented by formula (I) as well as isomers, pharmaceutically acceptab...
|
|
WO/2019/124544A1 |
Provided is a method for detecting trifluridine-derived analogs and/or tipiracil-derived analogs, including a step in which sample containing trifluridine or a salt thereof and tipiracil or a salt thereof is supplied to high-speed liquid...
|
|
WO/2019/122282A1 |
The present invention relates to a gapmer oligonucleotide comprising at phosphorodithioate internucleoside linkage of formula (I) as defined in the description and in the claims. The oligonucleotide of the invention can be used as a medi...
|
|
WO/2019/121734A1 |
The invention is in the field of medical sciences. It provides new pharmaceutical methods and preparations. In particular, the invention relates to a method for increasing the oral bioavailability of drugs. The invention also provides ne...
|
|
WO/2019/120300A1 |
Disclosed are an anticancer prodrug nucleoside cyclic phosphate compound based on liver-specific delivery (LSD) technology and the use thereof, in particular, provided are a compound of formula (I) and an isomer, a pharmaceutically accep...
|
|
WO/2019/122084A1 |
It relates to a process for the preparation of nicotinamide riboside chloride of formula (I) wherein R1-R4 are as defined herein, comprising the following steps: a) reacting a riboside precursor wherein the hydroxyl groups at positions 1...
|
|
WO/2019/122279A1 |
The present invention relates to an oligonucleotide comprising at least one phosphorodithioate internucleoside linkage of formula (I) (I) as defined in the description and in the claim. The oligonucleotide of the invention can be used as...
|
|
WO/2019/126482A1 |
Provided herein are crystalline forms of nicotinamide riboside chloride and methods of making the same. Also provided are compositions comprising the crystalline form of nicotinamide riboside chloride, and therapeutic methods employing t...
|
